Kajihara Mikio, Takakura Kazuki, Kanai Tomoya, Ito Zensho, Matsumoto Yoshihiro, Shimodaira Shigetaka, Okamoto Masato, Ohkusa Toshifumi, Koido Shigeo
Mikio Kajihara, Kazuki Takakura, Tomoya Kanai, Zensho Ito, Yoshihiro Matsumoto, Toshifumi Ohkusa, Shigeo Koido, Division of Gastroenterology and Hepatology, Department of Internal Medicine, the Jikei University School of Medicine (Kashiwa Hospital), Chiba 277-8567, Japan.
World J Gastroenterol. 2016 May 14;22(18):4446-58. doi: 10.3748/wjg.v22.i18.4446.
The incidence of pancreatic ductal adenocarcinoma (PDA) is on the rise, and the prognosis is extremely poor because PDA is highly aggressive and notoriously difficult to treat. Although gemcitabine- or 5-fluorouracil-based chemotherapy is typically offered as a standard of care, most patients do not survive longer than 1 year. Therefore, the development of alternative therapeutic approaches for patients with PDA is imperative. As PDA cells express numerous tumor-associated antigens that are suitable vaccine targets, one promising treatment approach is cancer vaccines. During the last few decades, cell-based cancer vaccines have offered encouraging results in preclinical studies. Cell-based cancer vaccines are mainly generated by presenting whole tumor cells or dendritic cells to cells of the immune system. In particular, several clinical trials have explored cell-based cancer vaccines as a promising therapeutic approach for patients with PDA. Moreover, chemotherapy and cancer vaccines can synergize to result in increased efficacies in patients with PDA. In this review, we will discuss both the effect of cell-based cancer vaccines and advances in terms of future strategies of cancer vaccines for the treatment of PDA patients.
胰腺导管腺癌（PDA）的发病率正在上升，且预后极差，因为PDA具有高度侵袭性且极难治疗。尽管以吉西他滨或5-氟尿嘧啶为基础的化疗通常作为标准治疗方案，但大多数患者生存期不超过1年。因此，为PDA患者开发替代治疗方法势在必行。由于PDA细胞表达众多适合作为疫苗靶点的肿瘤相关抗原，一种有前景的治疗方法是癌症疫苗。在过去几十年中，基于细胞的癌症疫苗在临床前研究中取得了令人鼓舞的结果。基于细胞的癌症疫苗主要通过将完整肿瘤细胞或树突状细胞呈递给免疫系统细胞来产生。特别是，多项临床试验已探索将基于细胞的癌症疫苗作为PDA患者一种有前景的治疗方法。此外，化疗和癌症疫苗可协同作用，提高PDA患者的疗效。在本综述中，我们将讨论基于细胞的癌症疫苗的作用以及癌症疫苗治疗PDA患者未来策略方面的进展。
